Pregled bibliografske jedinice broj: 257769
PMA and doxorubicin decrease viability, MTT activity, and expression of CD10 marker on NALM-1 leukemic cells.
PMA and doxorubicin decrease viability, MTT activity, and expression of CD10 marker on NALM-1 leukemic cells. // Immunopharmacology and Immunotoxicology, 28 (2006), 411-420 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 257769 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
PMA and doxorubicin decrease viability, MTT activity, and expression of CD10 marker on NALM-1 leukemic cells.
Autori
Martin-Kleiner, Irena ; Svoboda-Beusan, Ivna ; Gabrilovac, Jelka
Izvornik
Immunopharmacology and Immunotoxicology (0892-3973) 28
(2006);
411-420
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
pre-B leukemic cells; CD10; NALM-1; PMA; doxorubicin
Sažetak
PMA 10, 20 ng/ml) and doxorubicin (5-20 ng/ml) decreased the viability and MTT-activity of NALM-1 pre-B leukemic cells (3 days treatment). Further, CD10 was downregulated, suggesting that PMA and doxorubicin induced differentiation of NALM-1 cells. However, PMA did not alter expression of B cell markers CD20 and of mIgM. In contrast to PMA, another differentiation agent ATRA did not alter CD10 expression on NALM-1 cells but affected viability after 6 days (5, 10 ng/ml). The data on this study are the first evidence that PMA and doxorubicin inhibited viability and MTT activity and induced partial differentiation, by decreasing CD10 on NALM-1 cells.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE